Enter a keyword or phrase to search all pages in this section:


Advanced search

Archive:

Looking for a previously published document in this section?

CSM advice on liver toxicity associated with Kava-kava and proposed regulatory action by the Government - message from Professor A Breckenridge, Chairman, Committee on Safety of Medicines and the associated press release

A message is being sent to health professionals informing them that, following a provisional opinion from the CSM about the risk of liver toxicity associated with medicinal products containing the herbal ingredient Kava-kava, the MHRA is to consult on a proposal to prohibit the supply of medicinal products containing the substance. This advice applies to all medicinal products for internal use.

Page last modified: 14 November 2006